A California federal judge gave final approval to two settlements of class actions alleging that Teikoku, Endo and Actavis violated antitrust laws by stalling the release of a generic form of the Lidoderm pain patch. One class actin was on behalf of direct purchasers and settled for $166 million. The other was on behalf of end payors and settled for $104.75 million. Continue reading “Antitrust Class Actions Regarding Generic Lidoderm Pain Patch Settle for A Combined Amount Over $270 Million”